Vol. 148, No. 11 — March 15, 2014

GOVERNMENT NOTICES

DEPARTMENT OF HEALTH

DEPARTMENT OF HEALTH ACT

Notice of annual increase of Health Canada’s Drug Master Files and Certificate of a Pharmaceutical Product fees

Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, hereby updates the fees that are payable for the provision of Drug Master Files and Certificate of a Pharmaceutical Product services by 2%, beginning April 1, 2014. These fees will continue to be updated annually, with an automatic 2% increase to align with the Drug Program’s regulatory user fees.

This change is effective beginning on April 1, 2014. The current fees and the fees updated as of April 1, 2014, are listed below.

Any inquiries or comments about the updated fees can be directed to Diana Dowthwaite, Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 613-957-6690 (telephone), cri_irc_consultations@hc-sc.gc.ca (email).

Services

Fee as of April 1, 2013

Fee as of April 1, 2014

Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product)

$78

$80

Drug Master Files

$408

$416

Drug Master Files — letter of access

$184

$188

Drug Master Files — biannual updates

$184

$188

March 2, 2014

[11-1-o]

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual increase of fees

Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the 2011 Fees in Respect of Drugs and Medical Devices Regulations, every fee outlined by the Regulations is to be increased annually by 2%, rounded up to the nearest dollar.

This change was effective beginning on November 6, 2013. The revised fees and the fees updated as of April 1, 2014, are listed below.

Any inquiries or comments about the updated fees can be directed to Diana Dowthwaite, Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 613-957-6690 (telephone), cri_irc_consultations@hc-sc.gc.ca (email).

Fee Category

Section in Fees in Respect of Drugs and Medical Devices Regulations

Fee with Penalties as of November 6, 2013

Fee as of April 1, 2014

PART 2 — DRUGS

Fees For Examination Services — Schedule 1

New active substance

6

 

$322,056

Clinical or non-clinical data and chemistry and manufacturing data

6

 

$163,120

Clinical or non-clinical data only

6

 

$76,132

Comparative studies

6

 

$46,016

  • ANDS — Pharma only

6

$23,910

$24,388

  • SANDS — Pharma only

6

$22,557

$23,008

Chemistry and manufacturing data only

6

 

$21,756

  • ANDS — Pharma only

6

$15,144

$15,447

Published data only

6

 

$18,041

Switch status from prescription drug to non-prescription drug

6

 

$43,808

Labelling only

6

 

$2,931

Administrative submission

6

 

$303

Disinfectants

6

 

$4,055

Drug identification number application — labelling standards

6

 

$1,625

Remission

Remission processing fee

11(1)(a)(iii)

 

$532

Establishment Licence Fees

Fabrication of Drugs — Schedule 2

Basic fee

19(1), 27, 28(1)(a), 28(2)(a)

 

$16,397

Each additional category

19(1)(a)

 

$4,108

Dosage form classes

2 classes

19(1)(b)

 

$8,204

3 classes

19(1)(b)

 

$16,397

4 classes

19(1)(b)

 

$20,505

5 classes

19(1)(b)

 

$24,600

6 classes

19(1)(b)

 

$28,696

Each additional class

19(1)(b)

 

$1,646

Sterile dosage forms

19(1)(c)

 

$8,204

Packing/Labelling of Drugs — Schedule 3

Basic fee

20(1), 20(3)(a), 28(1)(b), 28(2)(b)

 

$10,963

Each additional category

20(1)(a)

 

$2,739

Dosage form classes

2 classes

20(1)(b)

 

$5,467

3 or more classes

20(1)(b)

 

$8,204

Importation and Distribution of Drugs — Schedule 4

Basic fee

21(a), 22, 28(1)(c) and (d), 28(2)(c) and (d)

 

$6,836

Each additional category

21(a)(i), 22(a)

 

$1,710

Dosage form classes

2 classes

21(a)(ii), 22(b)

 

$3,419

3 or more classes

21(a)(ii), 22(b)

 

$6,836

Each fabricator

21(b)(i)

 

$1,646

Each additional dosage form class for each fabricator

21(b)(ii)

 

$829

Distribution or Wholesaling

Distribution or wholesaling fee

23

 

$4,108

Testing

Testing fee

24

 

$2,739

Drug Analysis — Schedule 5

Vaccines (1)

25

 

$27,327

Drugs, not included in items 1, 6 and 9 of this Schedule, that are listed in Schedule D to the Food and Drugs Act

25

 

$10,932

Drugs for human use that are prescription drugs, controlled drugs or narcotics

25

 

$8,204

Drugs for human use, not included in any other item, for which a drug identification number has been assigned

25

 

$4,108

Radiopharmaceuticals

25

 

$0

PART 2 — DRUGS — Continued

Establishment Licence Fees — Continued

Drug Analysis — Schedule 5 — Continued

Whole blood and its components (6)

25

 

$0

Hemodialysis products

25

 

$0

Drugs that are labelled as disinfectants, including those listed in paragraph 9(f) of this Schedule, but excluding other drugs labelled as disinfectants of medical devices

25

 

$0

Drugs that meet the requirements of a class monograph having one of the following titles (9)

Acne therapies

25

 

$0

Antidandruff products

25

 

$0

Antiperspirants

25

 

$0

Antiseptic skin cleaners

25

 

$0

Athlete’s foot treatments

25

 

$0

Contact lens disinfectants 9(f)

25

 

$0

Fluoride-containing anti-caries products

25

 

$0

Medicated skin care products

25

 

$0

Sunburn protectants

25

 

$0

Throat lozenges

25

 

$0

Fees for the Examination of Dealer’s Licence Applications

Dealer’s Licence

Dealer’s licence

31(1)

 

$4,788

Fees for Right to Sell Drugs

Annual fee

35(1)

 

$1,084

PART 3 — MEDICAL DEVICE FEES

Fees for the Examination of Medical Device Licence Applications

Class II Medical Devices

Class II — Licence application

39(1)

 

$373

Class III Medical Devices — Schedule 6

Licence application

40(1)(a), 41(a)

 

$5,361

Licence application for near patient in vitro diagnostic device

40(1)(a), 41(a)

 

$9,127

Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing

40(1)(a), 41(a)

 

$1,349

Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations

40(1)(a), 41(a)

 

$5,021

Class IV Medical Devices — Schedule 7

Licence application

40(1)(b), 41(b)

 

$12,470

Licence application for devices that contain human or animal tissue

40(1)(b), 41(b)

 

$11,633

Licence application for near patient in vitro diagnostic device

40(1)(b), 41(b)

 

$21,257

Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing

40(1)(b), 41(b)

 

$1,349

Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations

40(1)(b), 41(b)

 

$5,721

Remission

Remission processing fee

44(1)(a)(iii)

 

$55

Fee for Right to Sell Licensed Class II, III or IV Medical Devices

Fee (if annual gross revenue of medical device sales is less than $20,000)

48(1)(a)

 

$55

Fee (in any other case)

48(1)(b)

 

$351

Fees for the Examination of an Application for an Establishment Licence

Medical devices establishment licence

51(1)

 

$7,641

March 2, 2014

[11-1-o]

DEPARTMENT OF INDIAN AFFAIRS AND NORTHERN DEVELOPMENT

CANADA PETROLEUM RESOURCES ACT

Results of the 2013-2014 Call for Bids for Exploration Licences in the Beaufort Sea and Mackenzie Delta

The Minister of Indian Affairs and Northern Development hereby gives notice pursuant to subsection 15(2) and section 19 of the Canada Petroleum Resources Act, R.S. 1985, c. 36, 2nd supplement, of the bid which was selected in response to the 2013-2014 Call for Bids for Exploration Licences in the Beaufort Sea and Mackenzie Delta. Once the winning bidder submits the issuance fee and work deposit, representing 25% of the work proposal bid, the winning bidder will be eligible to receive an exploration licence.

A summary of the terms and conditions applicable to the call was published in Part I of the Canada Gazette on October 19, 2013. The call closed at noon (MST) on February 25, 2014.

In accordance with the requirements set out in the 2013-2014 Call for Bids for Exploration Licences in the Beaufort Sea and Mackenzie Delta, the following bid has been selected:

Parcel BSMD2014-01 (47 945 hectares, more or less)

 

Work proposal bid:

$1,000,000

Work deposit:

$ 250,000

Issuance fee:

$ 750

Bidder:

Franklin Petroleum Canada Limited — 100%

Designated representative:

Franklin Petroleum Canada Limited

March 15, 2014

BERNARD VALCOURT, P.C., M.P.
Minister of Indian Affairs and Northern Development

[11-1-o]

DEPARTMENT OF INDIAN AFFAIRS AND NORTHERN DEVELOPMENT

NORTHWEST TERRITORIES AND NUNAVUT MINING REGULATIONS

Prospecting permits

1. The following are the areas in Nunavut in respect of which prospecting permits have been issued, effective February 1, 2014, pursuant to section 29 of the Northwest Territories and Nunavut Mining Regulations, C.R.C., c. 1516:

Number

Location (N.T.S.)

Permittee

8416

025O07NW/025O07N.-O.

Peregrine Diamonds Ltd.

8417

025O07SW/025O07S.-O.

Peregrine Diamonds Ltd.

8418

025P07SE/025P07S.-E.

Peregrine Diamonds Ltd.

8419

048A02NW/048A02N.-O.

MMG Resources Inc.

8420

048A02NE/048A02N.-E.

MMG Resources Inc.

8421

048A02SE/048A02S.-E.

MMG Resources Inc.

8422

048A06SE/048A06S.-E.

MMG Resources Inc.

8423

048A07SW/048A07S.-O.

MMG Resources Inc.

8424

065I06NW/065I06N.-O.

Canadian North Resources and Development Corporation

8425

065I16NW/065I16N.-O.

Canadian North Resources and Development Corporation

8426

065I05NW/065I05N.-O.

Canadian North Resources and Development Corporation

8427

065I05SE/065I05S.-E.

Canadian North Resources and Development Corporation

8428

065I15NE/065I15N.-E.

Canadian North Resources and Development Corporation

2. The following prospecting permits have been cancelled or relinquished in Nunavut:

Number

Location (N.T.S.)

Permittee

7783

057D05NE/057D05N.-E.

Diamonds North Resources Ltd.

7784

057S05NW/057S05N.-O.

Diamonds North Resources Ltd.

7785

057D05SE/057D05S.-E.

Diamonds North Resources Ltd.

7786

057D11SE/057D11S.-E.

Diamonds North Resources Ltd.

7882

058G06SE/058G06S.-E.

David Dupre

7910

047B09SW/047B09S.-O.

Advanced Explorations Inc.

7928

039E13SW/039E13S.-O.

Mark Raguz

7932

048E06NE/048E06N.-E.

Mark Raguz

7933

048E07NW/048E07N.-O.

Mark Raguz

7934

048E10NE/048E10N.-E.

Mark Raguz

7936

048E10SE/048E10S.-E.

Mark Raguz

7937

048E10SW/048E10S.-O.

Mark Raguz

7938

048E11NE/048E11N.-E.

Mark Raguz

7940

048E11SE/048E11S.-E.

Mark Raguz

7941

048E11SW/048E11S.-O.

Mark Raguz

7942

048H01NE/048H01N.-E.

Mark Raguz

7945

058G06NE/058G06N.-E.

Mark Raguz

7946

058H07NW/058H07N.-O.

Mark Raguz

8104

046B10NE/046B10N.-E.

Vale Inco Ltd.

8105

046B10SE/046B10S.-E.

Vale Inco Ltd.

8184

056D02NE/056D02N.-E.

Reginald Olson

8185

056D02SE/056D02S.-E.

Reginald Olson

8187

056E06SW/056E06S.-O.

Reginald Olson

8189

058C02NW/058C02N.-O.

David Dupre

8191

058C06NE/058C06N.-E.

David Dupre

8192

057C06SE/057C06S.-E.

David Dupre

8193

058C07NW/058C07N.-O.

David Dupre

8194

058C07SW/058C07S.-O.

David Dupre

8241

049G12NE/049G12N.-E.

Jordon Saulnier

8242

049G13SW/049G13S.-O.

Jordon Saulnier

8243

059F14NE/059F14N.-E.

Jordon Saulnier

8244

059G01NE/059G01N.-E.

Michel Saulnier

8245

059G01NW/059G01N.-O.

Michel Saulnier

8246

059G08NE/059G08N.-E.

Michel Saulnier

8247

059G08SE/059G08S.-E.

Michel Saulnier

8248

059G08SW/059G08S.-O.

Michel Saulnier

8249

059H02NW/059H02N.-O.

Michel Saulnier

8250

059H03NE/059H03N.-E.

Michel Saulnier

8251

059H03NW/059H03N.-O.

Michel Saulnier

8252

059H03SE/059H03S.-E.

Michel Saulnier

8253

059H03SW/059H03S.-O.

Michel Saulnier

8254

059H04NE/059H04N.-E.

Michel Saulnier

8255

059H04NW/059H04N.-O.

Michel Saulnier

8256

059H05NE/059H05N.-E.

Michel Saulnier

8257

059H05NW/059H05N.-O.

Michel Saulnier

8258

059H05SE/059H05S.-E.

Michel Saulnier

8259

059H05SW/059H05S.-O.

Michel Saulnier

8260

059H06NE/059H06N.-E.

Michel Saulnier

8261

059H06NW/059H06N.-O.

Michel Saulnier

8262

059H06SE/059H06S.-E.

Michel Saulnier

8263

059H06SW/059H06S.-O.

Michel Saulnier

8264

069E10NW/069E10N.-O.

Michel Saulnier

8266

069E10SW/069E10S.-O.

Michel Saulnier

8269

069F09SW/069F09S.-O.

Michel Saulnier

8270

069F10NE/069F10N.-E.

Karen Saulnier

8272

069F13SE/069F13S.-E.

Taina Saulnier

8273

069F13SW/069F13S.-O.

Michel Saulnier

8274

069F14NE/069F14N.-E.

Taina Saulnier

8275

069F14NW/069F14N.-O.

Taina Saulnier

8276

069F15NE/069F15N.-E.

Michel Saulnier

8277

069F15NW/069F15N.-O.

Taina Saulnier

8278

069G02SE/069G02S.-E.

Taina Saulnier

8279

069G02SW/069G02S.-O.

Taina Saulnier

8280

069G03NW/069G03N.-O.

Taina Saulnier

8281

069G03SE/069G03S.-E.

Taina Saulnier

8282

069G03SW/069G03S.-O.

Taina Saulnier

8283

079E16NE/079E16N.-E.

Taina Saulnier

8284

079E16SE/079E16S.-E.

Taina Saulnier

8308

076L06SE/076L06S.-E.

MMG Resources Inc.

8309

076L09NW/076L09N.-O.

MMG Resources Inc.

8310

076L09SW/076L09S.-O.

MMG Resources Inc.

8311

076L10SE/076L10S.-E.

MMG Resources Inc.

8312

076L13NW/076L13N.-O.

MMG Resources Inc.

8313

076L13SE/076L13S.-E.

MMG Resources Inc.

8314

076L13SW/076L13S.-O.

MMG Resources Inc.

8317

086I16NE/086I16N.-E.

MMG Resources Inc.

8318

086I16SE/086I16S.-E.

MMG Resources Inc.

8319

086P01NE/086P01N.-E.

MMG Resources Inc.

8320

086P01SE/086P01S.-E.

MMG Resources Inc.

8337

058C02SW/058C02S.-O.

Coltstar Ventures Inc.

8338

058C03NE/058C03N.-E.

Coltstar Ventures Inc.

8339

058C03SE/058C03S.-E.

Coltstar Ventures Inc.

8356

076L16SE/076L16S.-E.

MMG Resources Inc.

8357

076L16SW/076L16S.-O.

MMG Resources Inc.

8358

076M14SE/076M14S.-E.

MMG Resources Inc.

8359

076M04SW/076M04S.-O.

MMG Resources Inc.

8360

076M04SE/076M04S.-E.

MMG Resources Inc.

8361

076M05NE/076M05N.-E.

MMG Resources Inc.

8362

076M05SE/076M05S.-E.

MMG Resources Inc.

8363

076M05SW/076M05S.-O.

MMG Resources Inc.

8382

076F06NW/076F06N.-O.

Stewart Blusson

8383

076F06SW/076F06S.-O.

Stewart Blusson

8384

076F05NW/076F05N.-O.

Stewart Blusson

8385

076F05NE/076F05N.-E.

Stewart Blusson

8386

076F12NW/076F12N.-O.

Stewart Blusson

8387

076F12SW/076F12S.-O.

Stewart Blusson

8388

076F12SE/076F12S.-E.

Stewart Blusson

8389

076F12NE/076F12N.-E.

Stewart Blusson

8390

076F11NW/076F11N.-O.

Stewart Blusson

8391

076F11SW/076F11S.-O.

Stewart Blusson

8392

076F14SW/076F14S.-O.

Stewart Blusson

8393

076F13NW/076F13N.-O.

Stewart Blusson

8394

076F13SW/076F13S.-O.

Stewart Blusson

8395

076F13SE/076F13S.-E.

Stewart Blusson

8396

076E08NE/076E08N.-E.

Stewart Blusson

3. For information on expired prospecting permits, please contact the Nunavut Mining Recorder’s Office at 867-975-4275 (telephone) or 867-975-4286 (fax).

JEFF MERCER
Supervising Mining Recorder
Nunavut

[11-1-o]

DEPARTMENT OF INDUSTRY

RADIOCOMMUNICATION ACT

Notice No. SMSE-007-14 — Decision to rescind Broadcasting Procedures and Rules Part 5 (BPR-5) and Broadcasting Procedures and Rules Part 6 (BPR-6)

Notice is hereby given that the following Broadcasting Procedures and Rules are being withdrawn and are no longer in force, effective immediately:

BPR-5 provided application procedures and rules for DRB in the band 1452-1492 MHz, known as the L-band. In 2012, the Allotment Plan for Digital Radio Broadcasting (DRB) was rescinded through policy decision SP 1435 MHz, and other radio applications have been identified for the usage of this band.

BPR-6 provided application procedures and rules for MDS-TV services in the band 2596-2686 MHz. This band was transitioned to Broadband Radio Service (BRS) following the implementation of policy decision DGTP-002-06.

General information

In making the decision to rescind the above-mentioned documents, the Department consulted with industry through the Radio Advisory Board of Canada (RABC).

Obtaining copies

Copies of this notice and of documents referred to herein are available electronically on Industry Canada’s Spectrum Management and Telecommunications Web site at www.ic.gc.ca/spectrum.

Official versions of Canada Gazette notices can be viewed at www.gazette.gc.ca/rp-pr/p1/index-eng.html. Printed copies of the Canada Gazette can be ordered by telephoning the sales counter of Publishing and Depository Services at 613-941-5995 or 1-800-635-7943.

February 27, 2014

MARC DUPUIS
Director General
Engineering, Planning and Standards Branch

[11-1-o]

BANK OF CANADA

Statement of financial position as at December 31, 2013

(Millions of dollars) Unaudited

ASSETS

Cash and foreign deposits

 

5.0

Loans and receivables

Securities purchased under resale agreements

2,205.9

 

Advances to members of the Canadian Payments Association

 

Advances to governments

 

Other receivables

9.0

 
   

2,214.9

Investments

Treasury bills of Canada

21,586.4

 

Government of Canada bonds

66,653.6

 

Other investments

337.1

 
   

88,577.1

Property and equipment

 

232.4

Intangible assets

 

52.2

Other assets

 

224.1

 

91,305.7


LIABILITIES AND EQUITY

Bank notes in circulation

 

66,615.9

Deposits

Government of Canada

22,329.9

 

Members of the Canadian Payments Association

186.7

 

Other deposits

1,306.9

 
   

23,823.5

Liabilities in foreign currencies

Government of Canada

 

Other

 
   

Other liabilities

Securities sold under repurchase agreements

 

Other liabilities

431.1

 
   

431.1

   

90,870.5

Equity

Share capital

5.0

 

Statutory and special reserves

125.0

 

Available-for-sale reserve

305.2

 

Actuarial gains reserve

 

Retained earnings

 
   

435.2

91,305.7

I declare that the foregoing return is correct according to the books of the Bank.

Ottawa, February 13, 2014

S. Vokey
Chief Accountant and Chief Financial Officer

I declare that the foregoing return is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, February 13, 2014

Tiff Macklem
Senior Deputy Governor

[11-1-o]

BANK OF CANADA

Statement of financial position as at January 31, 2014

(Millions of dollars) Unaudited

ASSETS

Cash and foreign deposits

 

6.2

Loans and receivables

Securities purchased under resale agreements

 

Advances to members of the Canadian Payments Association

 

Advances to governments

 

Other receivables

8.6

 
   

8.6

Investments

Treasury bills of Canada

20,438.2

 

Government of Canada bonds

68,668.6

 

Other investments

346.7

 
   

89,453.5

Property and equipment

 

231.8

Intangible assets

 

51.3

Other assets

 

245.3

 

89,996.7


LIABILITIES AND EQUITY

Bank notes in circulation

 

63,734.8

Deposits

Government of Canada

23,846.2

 

Members of the Canadian Payments Association

207.2

 

Other deposits

1,238.7

 
   

25,292.1

Liabilities in foreign currencies

Government of Canada

 

Other

 
   

Other liabilities

Securities sold under repurchase agreements

 

Other liabilities

524.1

 
   

524.1

   

89,551.0

Equity

Share capital

5.0

 

Statutory and special reserves

125.0

 

Available-for-sale reserve

315.7

 

Actuarial gains reserve

 

Retained earnings

 
   

445.7

89,996.7

I declare that the foregoing return is correct according to the books of the Bank.

Ottawa, February 19, 2014

S. Vokey
Chief Accountant and Chief Financial Officer

I declare that the foregoing return is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, February 19, 2014

Stephen S. Poloz
Governor

[11-1-o]